CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

Abstract Objective Alzheimer’s disease (AD) is the sixth leading cause of death, with an average survival estimated between 5 and 10 years after diagnosis. Despite recent advances in diagnostic criteria of AD, few studies have used biomarker-based diagnostics to determine the prognostic factors of A...

Full description

Bibliographic Details
Main Authors: Adla Boumenir, Emmanuel Cognat, Severine Sabia, Claire Hourregue, Matthieu Lilamand, Aline Dugravot, Elodie Bouaziz-Amar, Jean-Louis Laplanche, Jacques Hugon, Archana Singh-Manoux, Claire Paquet, Julien Dumurgier
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
CSF biomarkers
β-amyloid peptide
Mortality
Online Access:http://link.springer.com/article/10.1186/s13195-019-0481-4

Internet

http://link.springer.com/article/10.1186/s13195-019-0481-4

Similar Items